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AbstrACt
Introduction Rapid detection of Shiga toxin-producing 
Escherichia coli (STEC) enables appropriate treatment. 
Numerous commercially available molecular tests exist, 
but they vary in clinical performance. This systematic 
review aims to synthesise available evidence to compare 
the clinical performance of enzyme immunoassay (EIA) and 
nucleic acid amplification tests (NAATs) for the detection 
of STEC.
Methods and analysis The following databases will 
be searched employing a standardised search strategy: 
Medline, Embase, Cochrane CENTRAL Register of 
Controlled Trials, Cochrane Database of Systematic 
Reviews, PubMed, Scopus and Web of Science. Grey 
literature will be searched under advice from a medical 
librarian. Independent reviewers will screen titles, 
abstracts and full texts of retrieved studies for relevant 
studies. Data will be extracted independently by two 
reviewers, using a piloted template. Quality Assessment 
of Diagnostic Accuracy Studies-2 will be employed to 
assess the risk of bias of individual studies, and the 
quality of evidence will be assessed with the Grading 
of Recommendations Assessment, Development and 
Evaluation approach. A bivariate random-effects model 
will be used to meta-analyse the sensitivity and specificity 
of commercial STEC diagnostic tests, and a hierarchical 
summary receiver operator characteristic curve will 
be constructed. Studies of single test accuracy of EIA 
and NAATs and studies of comparative accuracy will be 
analysed separately.
Ethics and dissemination Ethics approval was not 
required for this systematic review and meta-analysis. 
Findings will be disseminated in conferences, through a 
peer-reviewed journal and via personal interactions with 
relevant stakeholders.
PrOsPErO registration number CRD42018099119.
IntrOduCtIOn  
Shiga toxin-producing Escherichia coli (STEC) 
cause significant disease. Although proto-
typical E. coli O157:H7 is the leading cause 
of haemolytic uraemic syndrome (HUS), 
other STEC serotypes have been associated 
with severe disease and large outbreaks.1–4 
Multiple serotypes have now been linked to 
disease. Unlike the O157 serotype, detec-
tion of non-O157 serotypes has increased 
significantly in the past decade, though likely 
because of dissemination of technology to 
detect these organisms.5 Patients infected 
with STEC often seek care through emer-
gency departments (EDs), especially if they 
have bloody diarrhoea. Strong evidence 
suggests that antibiotics may increase the 
risk of developing HUS if administered 
to people infected with STEC,6–8 and a 
recent meta-analysis demonstrated that the 
early administration of fluids is associated 
with improved outcomes.9 Therefore, it is 
important that healthcare providers have a 
means of detecting STEC that is both rapid 
and applicable to any serotype.
Historically, STEC testing has focused on 
the O157 serogroup using culture on sorbi-
tol-MacConkey agar, leveraging its inability 
to ferment sorbitol.10 This attribute is not 
strengths and limitations of this study
 ► There is little evidence reviewing the relative clini-
cal performance of commercially available tests for 
Shiga toxin-producing Escherichia coli (STEC).
 ► A key strength of this study is the comprehensive 
comparison of enzyme immunoassays and nucleic 
acid amplification tests to inform clinical practice.
 ► A limitation is the lack of a common gold standard 
for STEC identification, which may introduce hetero-
geneity into our analysis.
 ► Another limitation is that the finding of a Shiga toxin 
(Stx) 1 producing STEC that does not also produce 
Stx2, especially in the absence of bloody diarrhoea, 
is of unclear clinical and epidemiological value.
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shared by other STEC serogroups, so they are overlooked 
if sorbitol-MacConkey agar culture is the only detection 
method employed. Further, culture can take days to yield 
results, delaying informed management.11 In light of the 
limitations of culture, enzyme immunoassay (EIA) and 
nucleic acid amplification tests (NAATs) have been devel-
oped to detect STEC irrespective of serogroup. Reflecting 
their popularity, the US Council of State and Territorial 
Epidemiologists has recently revised the probable STEC 
case definition to include laboratory evidence from EIA 
and NAAT.12
Numerous tests to detect STEC are commercially avail-
able.13 14 The EIAs detect Shiga toxin (Stx), and most 
NAATs detect the Stx genes Stx1 and Stx2, and some 
additionally seek a locus that is specific to the O157 sero-
group. For NAAT, STEC is often one of several entero-
pathogens detected by the assay. EIA has suboptimal 
sensitivity, particularly if a time-consuming enrichment 
step is not conducted.15–18 Commercial NAATs appear to 
be more sensitive, but results vary by study and test.19–21 
NAATs are more costly than traditional microbiological 
techniques owing to the equipment and consumables 
required to perform them. However, the higher cost 
may be compensated by increased ascertainment21 and/
or improved patient outcomes.22 As laboratories consider 
NAATs, it is crucial to identify the best testing strategy to 
support time-sensitive, cost-effective treatment decisions. 
Thus, we will conduct a systematic review of commercial 
EIA and NAAT for STEC detection to determine if and 
how their performance differs in terms of diagnostic test 
accuracy (DTA).
MEthOds And AnAlysIs
This systematic review and meta-analysis will be conducted 
in accordance with reporting requirements for Preferred 
Reporting Items for Systematic Reviews and Meta-anal-
yses statement (PRISMA). This protocol was prepared 
according to PRISMA-Protocol and PRISMA-DTA guide-
lines.23 24
research question
What is the accuracy of commercially available EIA and 
NAAT for the detection of STEC and how do they differ?
Eligibility criteria
 ► Participants: study participants with acute diarrhoea, 
who provide a stool specimen or rectal swab for diag-
nostic testing; any age or subpopulation.
 ► Setting: healthcare systems or medical facilities, 
including outpatient clinics, EDs, hospitals, long-
term care centres and similar, without geographical 
limitation.
 ► Index tests: any commercially available EIA or NAAT 
for the detection of Stx, or Stx1 and Stx2; NAAT for 
the identification of the O157 serogroup, if avail-
able. Included studies may assess the accuracy of 
commercially available EIA, NAAT or both, including 
comparative accuracy studies.
 ► Reference standard: at least one of the following: 
enhanced protocols, real-time PCR, sequencing and/
or other NAAT.
 ► Target condition: acute diarrhoea associated with 
STEC infection.
 ► Study designs: cross-sectional diagnostic accuracy 
studies, encompassing all studies with both index 
and reference tests conducted on stool samples/
swabs collected at a single point of time during the 
acute diarrhoea illness, including both single test and 
comparative accuracy studies.
 ► Report characteristics: years 2005 to present (2015 
to present for conference abstracts), published or 
unpublished, in any language.
literature searches
The following databases will be searched from 2005: 
MEDLINE, Cochrane CENTRAL Register of Controlled 
Trials, Cochrane Database of Systematic Reviews, EMBASE, 
PubMed, SCOPUS and Web of Science. Clinical trial data-
bases ( ClinicalTrials. gov), Food and Drug Administra-
tion applications, package inserts for commercial assays, 
company product websites and literature, government/
non-governmental organization reports and conference 
abstracts will also be searched under the advice of STEC 
subject experts and a medical librarian. The reference lists 
of included studies will be scanned to identify additional 
studies of relevance to this review. The specific search 
strategy can be found in online supplementary appendix I.
study records
Data management
Records retrieved will be uploaded into EndNote 
V.8 (Philadelphia, Pennsylvania, USA), and deduplicated 
using EndNote V.8 and Rayyan for Systematic Reviews 
(Qatar, 2018).
Selection process
Two reviewers (GAMT, CYL) will independently screen 
all titles and abstracts in duplicate, and a third reviewer 
(SBF) will adjudicate any disagreements. Studies will be 
included if the title and abstract indicate that the manu-
script may contain data related to the evaluation of EIA 
and/or NAAT for the detection of STEC. The full text of 
all potentially relevant citations will then be obtained and 
reviewed by two independent reviewers (GAMT, CYL) 
using the predefined eligibility criteria outlined above, 
with the involvement of a third reviewer (SBF) in case 
consensus cannot be reached. Reasons for inclusion and 
exclusion will be documented. A tool to document the 
selection process will be developed, piloted with the first 
25 search results and modified as necessary.
Data extraction
Two reviewers will extract data independently and in 
duplicate using a structured form. The form will be 
piloted on the first five included studies and modified as 
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necessary. Discordances will be resolved through discus-
sions involving the reviewers and subject matter experts. 
First and last study authors will be contacted if data neces-
sary to calculate sensitivity or specificity are absent from 
the manuscript. Study characteristics and study outcomes 
(table 1) will be extracted from included studies.
risk of bias assessments
To assess the risk of bias in individual studies, we will employ 
the Quality Assessment of Diagnostic Accuracy Studies-2 
(QUADAS-2).25 We will follow the recommended process 
for tailoring the QUADAS-2 to our systematic review, 
including iteratively tailoring the QUADAS-2 assessment 
tool and piloting it on at least five studies until consensus 
has been reached on a version of the tool.25 As part of 
this process, we will review the Standards for Reporting of 
Diagnostic Accuracy26 and prior QUADAS-2 modifications 
for comparative accuracy studies27 for relevant criteria. 
For comparative accuracy studies, we will add a signalling 
question regarding the assessment of EIA and NAATs in 
the same group of patients. The risk of bias in individual 
studies (for all outcomes reported) will be rated as low/
unclear/high.28 Assessments will be made independently 
by two reviewers, and disagreements will be resolved by 
discussion, or where necessary, by a third reviewer. Risk of 
bias will be reported for all included studies.
data synthesis
Separate synthesis will be conducted for EIA and NAAT. 
For each of test type, data will be quantitatively synthe-
sised if at least four studies have been identified. If the 
number of included studies for either EIA or NAAT is 
insufficient, point estimates and CIs from the individual 
papers will be shown, and the comparison of EIA and 
NAAT will be based on the range of estimates reported in 
individual papers.
If four or more studies are included for a given test 
type, a bivariate random-effects model29 will be used to 
calculate summary estimates and confidence intervals 
of primary outcomes and secondary outcomes, and a 
hierarchical summary receiver operating characteristic 
(ROC) curve30 will be constructed.31 The summary point 
for sensitivity and specificity with confidence ellipse and 
the hierarchical summary ROC curve will be graphed. 
These analyses take into account the correlation between 
sensitivity and specificity and potential threshold effects 
(eg, due to cycle thresholds used in PCR).31 Meta-analysis 
packages in R32 and RevMan33 will be used to conduct all 
analyses.
Comparative accuracy
To compare EIA and NAAT, we will meta-analyse only 
comparative accuracy studies that evaluate both types 
of the test against the same reference standard. If no 
comparative accuracy studies are identified, we will graph-
ically compare point estimates and CIs for sensitivity 
and specificity resulting from the separate meta-analysis 
of each type of test. If there is adequate consistency in 
reference standards used to assess single test accuracy, we 
will pool EIA and NAAT studies in a single meta-analysis 
and include test type as a covariate to test the difference 
in accuracy between EIA and NAAT.
subgroup analysis
To identify study characteristics that may be contributing 
to heterogeneity, we will conduct subgroup analyses when 
at least four studies are available per subgroup:
 ► Funding (industry vs other).
 ► Data source (published vs unpublished).
 ► Age (<10 years old and <18 years old).
 ► Location of care.
 ► Diarrhoea duration (<7 days, ≥7 days, not specified).
 ► Presence of bloody diarrhoea.
 ► Specimen type.
 ► Test brand.
 ► Test targets.
 ► Reference standard.
Other subgroup analyses not prespecified here will be 
identified as such in all reports. Subgroup analyses will 
illustrate the magnitude of differences in accuracy, and 
thus allow readers to interpret whether they are clinically 
meaningful. We will obtain statistical evidence of whether 
these factors contribute to heterogeneity in the primary 
analysis by adding each to the bivariate random-effects 
model as a predictor.
A sensitivity analysis excluding studies with a high risk 
of bias will be conducted. Additional sensitivity analyses 
will be added if other potential biases become apparent 
during the review.
Quality of evidence assessment
For the quality of evidence for each test type, two 
reviewers, one with clinical and one with methodological 
expertise, will independently use the Grading of Recom-
mendations Assessment, Development and Evaluation 
approach to assess the quality of evidence for sensitivity 
and specificity.34 35 The test will be considered in the 
context of how it relates to patient-important outcomes 
to assign importance to the consequences of summary 
sensitivity and specificity findings (eg, frequency of false 
negatives). The domains of study design, limitations/risk 
of bias, directness, consistency, precision and publication 
bias will be assessed and combined into a summary grade 
for all important outcomes of the test. Publication bias 
will be assessed based on differences in accuracy reported 
in industry-funded versus non-industry-funded studies.
For the comparison of EIA and NAAT, we will use a 
similar approach to grade the quality of evidence, with 
the same domains as for single test accuracy. Risk of bias 
will reflect the modifications we make to QUADAS-2 
for comparative accuracy studies. Indirectness will be 
affected by the number of comparative accuracy studies 
including both EIA and NAAT; if few comparative accu-
racy studies are identified and the comparison is based on 
single test accuracy from different studies, quality will be 
downgraded due to indirectness.
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Table 1 Data to be extracted from each included study
Item Rationale
Study characteristics
  Data source Peer-reviewed studies will be distinguished from non-peer-reviewed data for potential 
subgroup analysis
  Funding source Studies funded by diagnostic test companies may be subject to additional bias; potential 
subgroup analysis
  Study design Cross-sectional studies are expected; other study designs will be noted for potential 
subgroup analysis
  Population Population restrictions within the study (eg, by age, HUS status, etc) will be noted for 
potential subgroup analysis
  Setting Country or region; potential subgroup analysis
Clinical data
  Location of care Primary care versus ED versus hospital, and potentially other; potential subgroup analysis
  Diarrhoea definition Study definition for diarrhoea (eg, ≥3 episodes in 24 hours) will facilitate comparability 
assessment and interpretation
  Diarrhoea duration Mean/median or restrictions on illness duration at the time of sampling; facilitate 
comparability assessment and interpretation
  Specimen type Stool specimen or rectal swab; potential subgroup analysis
  Bloody diarrhoea Frequency of bloody diarrhoea; potential subgroup analysis
Test
  Brand name Ease of reference
  Type EIA or NAAT for main comparison
  Enrichment For EIA tests; potential subgroup analysis
  Targets Toxin versus DNA, STEC-only versus multianalyte; interpretation and potential subgroup 
analysis
  Cycle threshold Cycle cut-off for positivity; facilitate comparability assessment and interpretation
  Comparator/reference 
standard
Composite standard with component tests, discrepant analysis with confirmatory tests; 
interpretation and potential source of bias
  Specimen comparability Specimens tested by index and comparator from the same point in time, of the same type; 
potential source of bias
Outcomes
  Outcome type For STEC generally, Shiga toxin 1 vs 2 or O157 vs non-O157; distinguish primary and 
secondary outcomes
  No tested Outcome calculation and interpretation
  No confirmatory tested Outcome calculation and interpretation
  No of true positives Outcome calculation
  No of false positives Outcome calculation
  No of true negatives Outcome calculation
  No of false negatives Outcome calculation
  Sensitivity Primary outcome
  Specificity Primary outcome
  Single accuracy measures For example, AUC, diagnostic accuracy, diagnostic OR; secondary outcome
  PPV Secondary outcome
  NPV Secondary outcome
  LR+ Secondary outcome
  LR− Secondary outcome
AUC, area under the curve; ED, emergency department; EIA, enzyme immunoassay; HUS, haemolytic uraemic syndrome; LR, likelihood ratio; 
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Study results will be reported according to the PRIS-
MA-DTA guidelines.24
Patient and public involvement
This protocol was designed without patient involvement. 
Patients were not invited to comment on the systematic 
review design and were not consulted to develop patient-rel-
evant outcomes. Patients were not invited to contribute to 
the writing or editing of this protocol for readability or 
accuracy.
EthICs And dIssEMInAtIOn
Findings will be disseminated in conferences, through a 
peer-reviewed journal and via personal interactions with 
relevant stakeholders.
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